FI4021575T3 - Menetelmiä cln2-taudin hoitamiseksi lapsikohteissa - Google Patents
Menetelmiä cln2-taudin hoitamiseksi lapsikohteissa Download PDFInfo
- Publication number
- FI4021575T3 FI4021575T3 FIEP20771408.0T FI20771408T FI4021575T3 FI 4021575 T3 FI4021575 T3 FI 4021575T3 FI 20771408 T FI20771408 T FI 20771408T FI 4021575 T3 FI4021575 T3 FI 4021575T3
- Authority
- FI
- Finland
- Prior art keywords
- subject
- composition
- use according
- administered
- rhtppl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893535P | 2019-08-29 | 2019-08-29 | |
| PCT/US2020/048704 WO2021042020A1 (en) | 2019-08-29 | 2020-08-31 | Methods for treating cln2 disease in pediatric subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4021575T3 true FI4021575T3 (fi) | 2024-07-24 |
Family
ID=72470612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20771408.0T FI4021575T3 (fi) | 2019-08-29 | 2020-08-31 | Menetelmiä cln2-taudin hoitamiseksi lapsikohteissa |
Country Status (24)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12303693B2 (en) * | 2021-04-02 | 2025-05-20 | Neuropace, Inc. | Systems and methods for controlling operation of an implanted neurostimulation system based on a mapping of episode durations and seizure probability biomarkers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
| US20020006400A1 (en) | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| CA2803166C (en) * | 2010-06-25 | 2023-03-07 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| AU2016341428B2 (en) * | 2015-10-23 | 2021-12-02 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
| KR20260086827A (ko) * | 2018-11-14 | 2026-06-10 | 리젠엑스바이오 인크. | 신경원성 세로이드 리포푸신증에 대한 유전자 요법 |
-
2020
- 2020-08-31 EP EP24177169.0A patent/EP4438120A3/en active Pending
- 2020-08-31 LT LTEPPCT/US2020/048704T patent/LT4021575T/lt unknown
- 2020-08-31 CN CN202080068971.3A patent/CN114828960A/zh active Pending
- 2020-08-31 KR KR1020227010387A patent/KR20220054375A/ko active Pending
- 2020-08-31 EP EP20771408.0A patent/EP4021575B1/en active Active
- 2020-08-31 US US17/638,029 patent/US20220273775A1/en active Pending
- 2020-08-31 HR HRP20240871TT patent/HRP20240871T1/hr unknown
- 2020-08-31 WO PCT/US2020/048704 patent/WO2021042020A1/en not_active Ceased
- 2020-08-31 FI FIEP20771408.0T patent/FI4021575T3/fi active
- 2020-08-31 MX MX2022002451A patent/MX2022002451A/es unknown
- 2020-08-31 CA CA3152521A patent/CA3152521A1/en active Pending
- 2020-08-31 HU HUE20771408A patent/HUE067135T2/hu unknown
- 2020-08-31 AU AU2020336984A patent/AU2020336984B2/en active Active
- 2020-08-31 AR ARP200102442A patent/AR119871A1/es unknown
- 2020-08-31 JP JP2022513165A patent/JP2022546042A/ja active Pending
- 2020-08-31 ES ES20771408T patent/ES2987156T3/es active Active
- 2020-08-31 RS RS20240792A patent/RS65763B1/sr unknown
- 2020-08-31 PL PL20771408.0T patent/PL4021575T3/pl unknown
- 2020-08-31 SM SM20240315T patent/SMT202400315T1/it unknown
- 2020-08-31 SI SI202030455T patent/SI4021575T1/sl unknown
- 2020-08-31 PT PT207714080T patent/PT4021575T/pt unknown
- 2020-08-31 DK DK20771408.0T patent/DK4021575T3/da active
- 2020-08-31 BR BR112022003598A patent/BR112022003598A2/pt unknown
- 2020-08-31 HR HRP20220370AA patent/HRP20220370A1/hr not_active Application Discontinuation
-
2022
- 2022-02-21 IL IL290763A patent/IL290763A/en unknown
- 2022-02-28 CL CL2022000496A patent/CL2022000496A1/es unknown
-
2025
- 2025-08-12 JP JP2025134120A patent/JP2025165414A/ja active Pending
-
2026
- 2026-04-07 AU AU2026202611A patent/AU2026202611A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4021575B1 (en) | 2024-05-22 |
| JP2022546042A (ja) | 2022-11-02 |
| PL4021575T3 (pl) | 2024-09-23 |
| ES2987156T3 (es) | 2024-11-14 |
| HUE067135T2 (hu) | 2024-10-28 |
| MX2022002451A (es) | 2022-06-02 |
| RS65763B1 (sr) | 2024-08-30 |
| KR20220054375A (ko) | 2022-05-02 |
| SMT202400315T1 (it) | 2024-09-16 |
| EP4021575A1 (en) | 2022-07-06 |
| PT4021575T (pt) | 2024-07-30 |
| LT4021575T (lt) | 2024-08-12 |
| AR119871A1 (es) | 2022-01-19 |
| AU2020336984B2 (en) | 2026-04-23 |
| TW202122106A (zh) | 2021-06-16 |
| HRP20240871T1 (hr) | 2024-10-11 |
| US20220273775A1 (en) | 2022-09-01 |
| WO2021042020A1 (en) | 2021-03-04 |
| HRP20220370A1 (hr) | 2022-09-16 |
| CL2022000496A1 (es) | 2022-10-21 |
| JP2025165414A (ja) | 2025-11-04 |
| SI4021575T1 (sl) | 2024-10-30 |
| CN114828960A (zh) | 2022-07-29 |
| EP4438120A2 (en) | 2024-10-02 |
| AU2020336984A1 (en) | 2022-03-10 |
| IL290763A (en) | 2022-04-01 |
| AU2026202611A1 (en) | 2026-06-04 |
| CA3152521A1 (en) | 2021-03-04 |
| EP4438120A3 (en) | 2024-12-11 |
| BR112022003598A2 (pt) | 2022-05-24 |
| DK4021575T3 (da) | 2024-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | Intravenous infusion of magnesium sulphate after acute myocardial infarction: effects on arrhythmias and mortality | |
| FI3982960T3 (fi) | Perinnöllisen angioödeeman hoitoja | |
| FI3294345T3 (fi) | Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi | |
| Gottlieb et al. | Nifedipine in acute myocardial infarction: an assessment of left ventricular function, infarct size, and infarct expansion. A double blind, randomised, placebo controlled trial. | |
| Sayfullaevich | Clinical and pathogenetic approaches to early rehabilitation of ischaemic stroke patients | |
| US6258798B1 (en) | Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin | |
| Shao et al. | Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone | |
| ES2250749T3 (es) | Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil. | |
| CN103599115B (zh) | 一种组合物在制备抗癫痫药物中的应用 | |
| HRP20240871T1 (hr) | Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata | |
| O'Connor et al. | A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction | |
| US20130065823A1 (en) | Supplement for Strengthening the Muscles of a Human | |
| CN104013702A (zh) | 一种治疗高血压的熏洗足浴用中药 | |
| JP2022546042A5 (cg-RX-API-DMAC7.html) | ||
| AR131256A1 (es) | Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos | |
| CN115634243A (zh) | 双黄连治疗乌头碱中毒导致的心律失常药物中的应用 | |
| RU2218172C1 (ru) | Способ лечения псориаза | |
| RU2651767C1 (ru) | Способ лечения невралгии тройничного нерва | |
| RU2067446C1 (ru) | Способ лечения болевого синдрома при невралгии тройничного нерва и фантомных болей культи конечностей | |
| RU2801486C1 (ru) | Способ лечения атрофии зрительного нерва в постковидном периоде | |
| RU2773682C1 (ru) | Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, для лечения гестозов беременных первого триместра | |
| RU2468813C1 (ru) | Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения | |
| RU2004243C1 (ru) | Способ лечени псориаза | |
| Evans et al. | The effects of long term methyldopa in patients with hypoxic cor pulmonale | |
| JP5274071B2 (ja) | 線維筋痛症治療剤 |